EZH2 inhibtion and IFNy treatment of patient derived organoids [scRNA-Seq]
We report the transcriptomics of primary murine lung squamous cell carcinomas in mice treated with EZH2 inhibition and anti-PD1 Overall design: To understand the cellular heterogeneity and responses to EZH2 inhibition and anti-PD1 therapies in lung squamous cell carcinoma